CLDN7 and ovarian cancer: demonstrated that CLDN7 is highly expressed in 2774 and HeyA8 human ovarian cancer cells, and inhibiting CLDN7 significantly enhanced the response of 2774 and HeyA8 cells to cisplatin treatment.